SP2 and asthma: Evaluation of the immunomodulatory properties of thenew sp2-IGLs supports their TLR4 agonistic character bothin vitro and in vivo, with a cytokine signature characterized by highexpression levels of IFNγ, suggesting a Th1-biased profile.Interestingly, the compounds were found to counteract the Th2 proinflammatorycontext in a mouse model of OVA-induced respiratory hyperreactivitymimicking asthma, promoting crisis resolution.